✦ LIBER ✦

A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients

✍ Scribed by De Pas, Tommaso; Putzu, Carlo; Curigliano, Giuseppe; Noberasco, Cristina; Sabrina, Boselli; Catania, Chiara; Orlando, Laura; Milani, Alessandra; Spaggiari, Lorenzo; de Braud, Filippo

Book ID: 119319488
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 210 KB
Volume: 54
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2006.08.016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Erratum to“A proper schedule of weekly p

Erratum to“A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients” [Lung cancer 54 (2006) 359–364]

✍ De Pas, Tommaso; Putzu, Carlo; Curigliano, Giuseppe; Noberasco, Cristina; Bosell 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 87 KB

21 Weekly paclitaxel and three weekly do

21 Weekly paclitaxel and three weekly docetaxel appear active and well-tolerated in third and fourth-line advanced NSCLC patients

✍ Pender, A.; Letsa, I.; Reid, A.; Waddell, T.; Nimako, K.; Tan, D.; Xynos, I.; Ay 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 44 KB

8035 POSTER The Combination of Weekly Ca

8035 POSTER The Combination of Weekly Carboplatin and Paclitaxel is Active and Tolerated for the Treatment of Advanced Ovarian Cancer in Elderly Patients

✍ Luqini, A.; Pace, R.; Capparella, V.; Ciorra, A.A.; Sciacca, V.; Pistillucci, G. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Weekly carboplatin and paclitaxel is saf

Weekly carboplatin and paclitaxel is safe, active, and well tolerated in recurrent ovarian cancer cases of Japanese women previously treated with cisplatin-containing multidrug chemotherapy

✍ A. Kikuchi; H. Sakamoto; T. Yamamoto 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB

Combination therapy with rituximab and i

Combination therapy with rituximab and interferon (IFN)-α-2a is `active, safe, and well tolerated' in patients with non-Hodgkin's lymphoma

📂 Article 📅 2000 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

ZD1839 (‘Iressa’), an orally-active, sel

ZD1839 (‘Iressa’), an orally-active, selective, epidermal growth factor receptor tyrosine kinase inhibitor (egfr-tki), is well tolerated in combination with gemcitabine and cisplatin, in patients with advanced solid tumours: preliminary tolerability, efficacy and pharmacokinetic results

✍ G. Giaccone; J.L. Gonzales-Larriba; E.F. Smit; A.T. van Oosterom; M. Martins; G. 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 338 KB